Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
2007 1
2008 2
2009 8
2010 10
2011 13
2012 10
2013 9
2014 18
2015 22
2016 25
2017 14
2018 18
2019 25
2020 33
2021 25
2022 27
2023 30
2024 33
2025 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. Among authors: alkhouri n. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Challenges and opportunities in NASH drug development.
Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Harrison SA, et al. Among authors: alkhouri n. Nat Med. 2023 Mar;29(3):562-573. doi: 10.1038/s41591-023-02242-6. Epub 2023 Mar 9. Nat Med. 2023. PMID: 36894650 Review.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R; 1404-0043 Trial Investigators. Sanyal AJ, et al. Among authors: alkhouri n. N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7. N Engl J Med. 2024. PMID: 38847460 Free article. Clinical Trial.
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Harrison SA, et al. Among authors: alkhouri n. Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. Lancet. 2019. PMID: 31727409 Clinical Trial.
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
Noureddin M, Charlton MR, Harrison SA, Bansal MB, Alkhouri N, Loomba R, Sanyal AJ, Rinella ME. Noureddin M, et al. Among authors: alkhouri n. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2367-2377. doi: 10.1016/j.cgh.2024.07.003. Epub 2024 Jul 20. Clin Gastroenterol Hepatol. 2024. PMID: 39038768 Free article. Review.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, Bedossa P, Harrison SA, Lazas D, Barish R, Gottwald MD, Feng S, Agollah GD, Hartsfield CL, Mansbach H, Margalit M, Abdelmalek MF. Loomba R, et al. Among authors: alkhouri n. N Engl J Med. 2023 Sep 14;389(11):998-1008. doi: 10.1056/NEJMoa2304286. Epub 2023 Jun 24. N Engl J Med. 2023. PMID: 37356033 Free PMC article. Clinical Trial.
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Eslam M, et al. Among authors: alkhouri n. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):864-873. doi: 10.1016/S2468-1253(21)00183-7. Epub 2021 Aug 6. Lancet Gastroenterol Hepatol. 2021. PMID: 34364544 Review.
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, Eguchi Y, Castera L, Pessoa MG, Oliveira CP, El-Kassas M, Tsochatzis E, Fan JG, Spearman CW, Tacke F, Castellanos Fernandez MI, Alkhouri N, Schattenberg JM, Romero-Gómez M, Noureddin M, Allen AM, Ong JP, Roberts SK, Shubrook JH, Burra P, Kohli R, Kautz A, Holleboom AG, Lam B, Isaacs S, Macedo P, Gastaldelli A, Henry L, Ivancovsky-Wajcman D, Nader F, de Avila L, Price JK, Mark HE, Villota-Rivas M, Barberá A, Kalligeros M, Gerber LH, Alqahtani SA. Younossi ZM, et al. Among authors: alkhouri n. Gastroenterology. 2025 Oct;169(5):1017-1032.e2. doi: 10.1053/j.gastro.2025.02.044. Epub 2025 Apr 11. Gastroenterology. 2025. PMID: 40222485 Free article.
308 results